Announcements
- Addex Reports Full Year 2022 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
- Addex Announces Upcoming Conferences it will participate for H1 2023
- Addex Regains Nasdaq Listing Compliance
- Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1
- Addex Provides Corporate Update and Financial Guidance
- Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
- Addex Reports Q3 2022 Financial Results and Provides Corporate Update
- Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
- Addex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 1.37 |
Average volume | -- |
---|---|
Shares outstanding | 115.35m |
Free float | 70.80m |
P/E (TTM) | -- |
Market cap | 20.76m CHF |
EPS (TTM) | -0.5532 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019 14:58 BST.
More ▼